Kyntra Bio Inc (KYNB) Institutional Buying & Selling Tracker (Q2 2026)

KYNB ranks #7631 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

28 institutions disclose a position in KYNB, but none treat it as a major bet — even Birchview Capital, LP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Tower Research Capital LLC has added to its KYNB position for two straight quarters, increasing it by $6.5K to reach $8.4K today.

Two Sigma Investments, LP has trimmed its KYNB position for two straight quarters, cutting it by $239.1K while still holding $298.3K.

KYNB posted net income of $183.2M over the trailing twelve months, and currently trades at a P/E of 0.2.

• Profitable — net income of $183.2M over the trailing twelve months
• Revenue grew 103.9% year over year
• Net income improved year over year, from -$2.1M to $183.2M
• Operating cash flow was negative, using $4.8M in cash
• Current ratio of 3.39x — enough short-term assets to cover short-term liabilities